The present issue of United European Gastroenterology Journal features a paper by Iris JM Levink et al., assessing "the additive value of CA19-9 monitoring in a pancreatic cyst surveillance program" using the data generated by the PACYFIC-registry work group. Serum carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex with a role in cell-to-cell recognition processes and needs for expression of Lewis blood group antigen (absent in 5%-10% of population). It is the most used tumor marker for the diagnosis, prognosis, and management of pancreatic cancer. 1 Consequently, it is making cannot be based solely on its elevated value, CA19-9 is still currently useful, especially when viewed in the context of the entire spectrum of each patient's characteristics. New International Guidelines on PC are in the pipeline, and CA19-9 will likely maintain its not negligible role. However, advances in this field appear to be more in the form of new biomarkers like next generation sequencing for specific mutations, 8 serum proteome, 9 tumor microenvironment and microbiome, 10 and deep learning and artificial intelligence. 11
CONFLICT OF INTEREST STATEMENT